<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 17, 2025, GSK issued a press release announcing “that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.” On this news, GSK’s American Depositary Receipt (“ADR”) price fell $1.81 per share, or 4.73%, to close at $36.47 per share on July 17, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETTBOQ00zTURnNE1ESTRJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETTBOQ00zTURnNE1ESTRJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODFlMzQzMjEtYzU2OC00ODVmLWJiMGQtNmM0ZWY4MTkwODI5LTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODFlMzQzMjEtYzU2OC00ODVmLWJiMGQtNmM0ZWY4MTkwODI5LTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

葛兰素史克

Pomerantz 律师事务所正在代表 GSK plc 投资者调查有关该公司及其高管可能存在的证券欺诈或非法商业行为的索赔。这一调查是由于 2025 年 7 月 17 日 FDA 顾问委员会对 GSK 的 Blenrep 的利益/风险评估投票反对，导致其 ADR 价格下跌 4.73%。鼓励投资者联系该事务所以获取有关加入集体诉讼的更多信息

投资者警报：Pomerantz 律师事务所代表葛兰素史克公司的投资者进行索赔调查 - GSK